You are here

P&T® Journal contents for April 2009

Features

Health Care & Law
Information about physician behavior, including malpractice judgments, is becoming more public now, especially on the Internet, and many health care professionals are concerned about Web-based patient critiques. Two court cases show that although physician privacy has prevailed, it is expected to face ongoing challenges.
Robert I. Field, JD, MPH, PhD
In a retrospective study, 100 mg of micafungin given once daily was as cost-effective as the 150-mg dose and yielded significant savings of $300 per patient.
Kwaku Marfo, PharmD, BCPS, and Yi Guo, PharmD
Topics include febuxostat (Uloric) in managing excess uric acid in gout; Hylan G-F 20 (Synvisc-One) for treating pain in osteoarthritis; and fibrinogen concentrate (RiaSTAP), an orphan drug to treat acute bleeding in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
Cancer and Chronic Lyme Disease
Discussions include supplements and herbs for breast cancer; chemoprotectant ribosomal RNA for advanced cancer; and conventional drugs with complementary therapies for patients with Lyme disease and other tick-borne disorders.
Walter Alexander
Continuing Education Credit
A Review of Treatment Options
Spontaneous bacterial peritonitis (SBP) often affects patients with cirrhosis and ascites. The authors review the pathogenesis and diagnosis of SBP, differentiate between primary SBP and secondary peritonitis, and discuss current therapies.
Cesar Alaniz, PharmD, and Randolph E. Regal, PharmD

Departments

Editorial
Although skeptics say fixing Big Pharma is not possible, David B. Nash, MD, MBA, describes a “cultural revolution” in which small elite groups within centers of excellence could revitalize R&D.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, highlights the need for vigilance with promethazine (Phenergan), which has caused tragic effects when it was not administered properly.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses the challenges facing comparative effectiveness research and how the $1.1 billion from the stimulus package might be divided up.
Stephen Barlas
From cethromycin to Seroquel, P&T presents the latest data on FDA approvals, indications, and industry updates.
Drug Forecast
Drs. Hilas and Ezzo review nebivolol (Bystolic), a beta blocker for hypertension.
Olga Hilas, PharmD, BCPS, CGP, and Danielle Ezzo, PharmD, BCPS, CGP